Jawline and neck treatment satisfaction in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolls adults with moderate to severe jawline and neck concerns to receive selected cosmetic products (onabotulinumtoxinA, SKINVIVE, VOLUX, VOLUMA) in the jaw area and neck. It aims to measure changes in satisfaction with lower face, jawline, and skin appearance, along with psychological well-being related to appearance. Participants will have clinic visits for medical assessments, vital signs, examinations, safety checks, and questionnaires to track outcomes and adverse events. The study follows eligibility criteria to identify appropriate candidates and will assess both aesthetic changes and patient-reported outcomes. Investigational products will be administered per standard clinical practice under supervision at two Canadian sites.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Moderate or severe transverse neck lines based on investigator's live assessment
* Moderate or severe loss of jawline definition based on investigator's live assessment.
* Moderate or severe platysma prominence based on investigator's live assessment.

Exclusion Criteria:

* History of or current medical condition that may put the subject at increased medical risk with exposure to BOTOX, or any other condition that might interfere with neuromuscular function.
* History of or current symptoms of dysphagia.
* History of severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies.
* History of hypersensitivity or allergy to any botulinum toxin serotype, Streptococcal or gram-positive bacterial proteins, lidocaine, HA products, any other excipients or constituents of the study drug, device, and/or other products in the same class.
* History of or tendency for keloid formation, hyperpigmentation, or hypertrophic scarring.

Where it's running

• Humphrey & Beleznay Cosmetic Dermatology /ID# 282598
  Vancouver, British Columbia, Canada Recruiting
• Sweat Clinics Of Canada /ID# 281845
  Toronto, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How trosunilimab moves through the body after IV and SC doses in healthy adults

  This study tests how trosunilimab behaves in the body and how the immune system reacts to it after intravenous and subcutaneous doses in healthy adults.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07925983

• Real-world use of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer

  This study tests how mirvetuximab soravtansine works in real-world adults with FRα-positive platinum-resistant ovarian, fallopian tube, or peritoneal cancer.

  Recruiting AbbVie · Vienna · NCT07896421

• NOA HYDRATION facial gel: see if it can improve skin smoothness

  This study tests whether NOA HYDRATION injectable gel can improve facial skin quality and smoothness in Chinese adults.

  Recruiting at 4 sites Phase 3 AbbVie · Beijing, Beijing Municipality and 3 other locations · NCT07880756

• Combination of two botulinum toxins for upper facial lines in adults

  This study tests whether a single treatment that combines trenibotulinumtoxinE with onabotulinumtoxinA can improve moderate to severe upper facial lines in adults.

  Recruiting at 21 sites Phase 2 AbbVie · Birmingham, Alabama and 20 other locations · NCT07871513

• ABBV-7828 safety and food effect study in healthy adults

  This study tests ABBV-7828 versus placebo in healthy adults to see how safe it is, how it behaves in the body, and how food changes its effects.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07856706

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.